Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: A phase III, open-label, randomized study.
Javier Cortes
Consultant or Advisory Role - Celgene; Novartis; Roche
Honoraria - Celgene; Novartis; Roche
Ahmad Awada
Consultant or Advisory Role - Eisai
Peter Andrew Kaufman
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Louise Yelle
Research Funding - Eisai
Edith A. Perez
No relevant relationships to disclose
Galina Velikova
Consultant or Advisory Role - Eisai (U)
Jantien Wanders
Employment or Leadership Position - Eisai
Martin S. Olivo
Employment or Leadership Position - Eisai
Yi He
Employment or Leadership Position - Eisai
Corina Dutcus
Employment or Leadership Position - Eisai
W. Robert Simons
Employment or Leadership Position - Eisai
Christopher Twelves
Consultant or Advisory Role - Eisai
Honoraria - Eisai